Product Description
AU14-5 is a highly potent oral CDK2 inhibitor that exhibits an excellent selectivity for CDK2 over a panel of 360 human protein kinases. It inhibits cancer cell proliferation and demonstrates excellent anticancer efficacy without any overt toxicity in animal models including ovarian and triple negative breast cancers, as well as leukaemia. Currently, AU14-5 is in late stage of preclinical development. (Sourced from: https://www.aucentra.com/drug-development-pipeline/#AU2-85)
Mechanisms of Action: CDK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aucentra
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|